Alzheimer Society launches first-ever Canadian Charter of Rights for People with Dementia
Charter written by and for people living with dementia
TORONTO, Sept. 5, 2018 /CNW/ - Today, the Alzheimer Society of Canada is pleased to officially launch the first-ever Canadian Charter of Rights for People with Dementia.
The landmark Charter is the culmination of over a year's work by the Society's Advisory Group of people with dementia, whose members represent different walks of life from across the country. With the number of Canadians with dementia expected to hit nearly one million in less than 15 years, the Advisory Group set out to define a set of seven explicit rights to give a greater voice and authority to those with dementia. The Charter will help people with dementia as well as their families challenge situations where they experience stigma, are treated unfairly, discriminated against, or are denied access to appropriate care.
The Charter empowers Canadians with dementia to self-advocate while also ensuring that the people and organizations that support them know and protect their rights. These include the right:
- to be free from discrimination of any kind.
- to benefit from all of Canada's civic and legal rights.
- to participate in developing and implementing policies that affect their life.
- to access support and opportunities to live as independent and engaged citizens in their community.
- to be informed and supported so they can fully participate in decisions affecting their care and life, from the point of diagnosis to palliative and end-of-life care.
- to expect that professionals involved in all aspects of their care are trained in dementia and human rights and are accountable to uphold these rights.
- to access effective complaint and appeal procedures when their rights are not protected or respected.
"People with dementia, no matter the stage of their disease, have the same rights as every other citizen," says Pauline Tardif, CEO of the Alzheimer Society of Canada. "Yet, we know all too well that Canadians with dementia continue to face cultural, social and economic barriers to claiming these rights, leaving many facing discrimination, isolation and treatment that contravenes their basic rights as human beings. We're asking all Canadians to champion this new Charter."
The Charter will not only help combat the ongoing stigma associated with dementia, but also help inform a rights-based approach to the development of services and supports for Canadians with dementia. In particular, it will serve to guide the federal government as it follows through on its commitment to develop and implement a national dementia strategy for Canada.
British Columbia resident Mario Gregorio, one of the Advisory Group members who contributed to the Charter, says, "As a person living with dementia, it gives me confidence to know that I'm not alone and reassurance that my country, my health and social services and my family, friends and community are there to lend a hand. We, as a nation, need to play a leadership role to ensure that people with dementia are not marginalized."
Throughout the month of September, the Society will feature stories written by some of the Advisory Group members on what the Charter means to them, and invite others impacted by dementia to comment. To read the stories, learn more about the Charter and download a free copy, in English or French, visit alzheimer.ca/Charter.
Notes to editors:
The Canadian Charter of Rights for People with Dementia is guided by a human rights-based approach known as "PANEL," endorsed by the United Nations. This approach emphasizes: the rights of everyone to participate in all decision-making directing their quality of life and care; accountability, holding individuals, communities and organizations responsible for recognizing, protecting and fulfilling their rights; non-discrimination, to self-advocate and challenge stigma; empowerment, to know their rights and how to claim these; and legality, to have assurance their rights are understood and followed according to law.
SOURCE Alzheimer Society of Canada
Bold Statement from Leukemia & Lymphoma Society of Canada Highlights the Pivotal Role of Blood Cancer Research in Advancing Breathroughs for Other Cancers and Diseases
Beating Cancer Is In Our Blood campaign making its debut during Blood Cancer Awareness Month and is expected to raise $200,000 for blood cancer research this September.
TORONTO, Sept. 5, 2018 /CNW/ - This month, The Leukemia & Lymphoma Society of Canada (LLSC) introduces– its Beating Cancer Is In Our Blood campaign– in a move to bring both the organization and blood cancers out of obscurity to mark Blood Cancer Awareness Month.
"Few people know that many of today's fundamental treatments for various cancers, like chemotherapy, began with blood cancer research," explains Alicia Talarico, LLSC president. "Fewer still know that our organization has been funding research since our inception in 1955." It is this collective history that literally substantiates "Beating Cancer Is In Our Blood".
Many lifesaving discoveries can be attributed to blood cancers. From the early development of chemotherapy and uncovering the inner workings of the immune response through to the discovery of cancer stem cells, blood cancer research has led the way to breakthroughs in other cancers and areas of medicine. Most recently, in 2017, CAR T-cell immunotherapy was developed and approved for use in blood cancer patients and is now being studied across multiple tumour types in 500 open trials.
Scientists studying blood cancers have a unique advantage to make groundbreaking discoveries. Cancer cells found in the blood are more accessible than those in solid tumours. In essence, it is easier to study cancer-causing molecules, measure the effects of new therapies and make pivotal discoveries that are applicable to other diseases.
Throughout the month of September, LLSC is letting Canadians know that when they support blood cancer research, they are doubling their impact with donations matched, up to $100,000, by iA Financial Group. Donate at llscanada.org.
There are 137 types of blood cancers and associated disorders that affect over 138,000 Canadians today. In 2018, LLSC awarded $3.7 million in grants to world-class researchers in Canada. Researchers are encouraged to apply for the 2019 Research Grants competition now until October 26, 2018. Learn more at llscanada.org.
About The Leukemia & Lymphoma Society Canada
The Leukemia & Lymphoma Society of Canada is the single largest voluntary health agency dedicated to blood cancers in Canada. LLSC funds life-saving blood cancer research across the country, and provides free information and support services to patients and caregivers. Our mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. To find out more visit llscanada.org.
SOURCE The Leukemia & Lymphoma Society of Canada
CGPA Statement on the Resumption of US-Canada Trade Talks
TORONTO, Sept. 5, 2018 /CNW/ - The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), on the resumption of trade negotiations between the United States and Canada:
It is CGPA's understanding that there are many US proposals on the table that would require changes to Canadian law and delay competition from generic and biosimilar medicines, including longer periods of data protection for biologic drugs. Biologic medicines represent the fastest growing cost segment of health care spending.
If such proposals were adopted they would create billions of dollars in new costs for employers who sponsor employee drug benefit programs, governments, and patients who pay for medicines out of pocket.
Canada's intellectual property regime for pharmaceuticals was amended in September 2017 as a result of the Comprehensive Economic and Trade Agreement (CETA) with the European Union. The Parliamentary Budget Officer has conservatively estimated that the two-year patent term extension included in CETA will cost Canadians more $600 million annually.1 It is our understanding that the measures pursued by the US in the negotiations go far beyond the measures included in CETA, and would be far more harmful for Canadians if adopted.
The Government of Canada says it is committed to improving access to necessary prescription medication and reducing the amounts Canadian governments pay for these drugs.2 As such, the Government of Canada must not agree to NAFTA concessions that reduce access to essential medicines and increase costs for those who pay for drugs.
Prime Minister Trudeau and Foreign Affairs Minister Freeland have stated repeatedly that they will only sign an agreement that is in the best interests of Canadians. Canada already has a strong intellectual property regime for pharmaceuticals. There are no concessions in the area of pharmaceutical intellectual property that are in the best interests of Canadians.
About the Canadian Generic Pharmaceutical Association
The Canadian Generic Pharmaceutical Association (CGPA) represents Canada's generic pharmaceutical industry. The industry plays an important role in controlling health-care costs in Canada. Generic drugs are dispensed to fill more than 71 percent of all prescriptions but account for account for only 21 percent of the $28-billion Canadians spend annually on prescription medicines.
________________________________________
1 http://www.pbo-dpb.gc.ca/web/default/files/Documents/Reports/2018/Patent%20Restoration/Patent_Restoration_EN.pdf
2 https://pm.gc.ca/eng/minister-health-mandate-letter
SOURCE Canadian Generic Pharmaceutical Association
The Arthritis Society and pt Health Partner to Decrease Pain and Improve the Quality of Life for Canadians Living with Arthritis
Partnership supports arthritis awareness, physiotherapy education, drug-free treatments, and early diagnosis for the prevention of arthritis.
TORONTO, Sept. 5, 2018 /CNW/ - The Arthritis Society and pt Health, a community clinic network with more than 230 locations across Canada, are proud to announce they have formalized a partnership focused on the benefit of physiotherapy to Canadians living with or at risk of developing arthritis. Specifically, the partnership will concentrate on increasing arthritis awareness, early detection and prevention, as well as the benefits of adding a Physiotherapist with increased arthritis knowledge to a patient's treatment team. The goal of the program is to help patients living with arthritis realize the potential benefits of a drug-free treatment plan that may offer relief from chronic pain and discomfort as well as an improved quality of life.
"We know that more than six million Canadians live with arthritis and that the demand for real relief is only increasing," says Heather Shantora, CEO, pt Health. "Physiotherapy has the potential to help reduce symptoms and help arthritis patients regain their quality of life. Together with the Arthritis Society, we are applying the best of what we know about arthritis to help offer patients an alternative to the pain they live with."
Today, arthritis affects over 6 million Canadians. i Osteoarthritis (OA) is the most prevalent form of the disease. ii By 2040, it is estimated that more than 10 million or one in four Canadians will have OA. iii Similarly, the economic burden of arthritis on our society, with estimated direct and indirect costs of over $33 billion annually, is expected to rise.iv
Access to trained physiotherapists is a key component of reducing the personal and social burden of the condition. "The Arthritis Society recognizes physiotherapists as a valuable part of an arthritis patient's treatment team," says Janet Yale, CEO, Arthritis Society. "Recognizing the life-changing impact that a physiotherapist with expertise in arthritis can have on quality of life for someone living with arthritis, the Arthritis Society is proud to work with pt Health to help ensure professional development resources are available to help physiotherapists and other healthcare professionals offer better care to people with arthritis."
This partnership is designed to help educate patients and caregivers about the condition. "It's time to change our mindset about arthritis," says Yale. "It is no longer necessary for someone to simply accept living with pain when they receive a diagnosis of arthritis."
As part of the program, pt Health physiotherapists will develop individualized programs, customized for each patient's unique needs, to help decrease inflammation, strengthen the muscles around the joint, increase range of motion, and reduce pain.
The partnership took effect on September 1, 2018.
About the Arthritis Society
The Arthritis Society is a national health charity, fueled by donors and volunteers, with a vision to live in a world where people are free from the devastating effects that arthritis has on lives. Beginning in 1948 with one very clear goal – to alleviate the suffering of people impacted by arthritis – that same volunteer-led passion carries on today in communities across Canada. Through the trust and support of our donors and sponsors, the Arthritis Society is Canada's largest charitable source of investments in cutting-edge arthritis research, proactive advocacy and innovative solutions that will deliver better health outcomes for people affected by arthritis. The Arthritis Society is accredited under Imagine Canada's Standards Program. For more information and to make a donation, visit arthritis.ca.
About pt Health
pt Health is the largest woman-lead physical rehabilitation company in Canada. With a network of over 230 clinics across Canada serving over 3,000 patients a day, each pt Health clinic offers a unique and integrated combination of physiotherapy, massage therapy, chiropractic care, and acupuncture, all with a 97% patient satisfaction score.
Learn more about pt Heath's commitment to excellent patient care at pthealth.ca
SOURCE pt Health
Passion and Purpose
CINCINNATI, OH – Passion and purpose are the cornerstones of the UI&U Master of Arts with a major in Clinical Mental Health Counseling and Alcohol and Drug Abuse Counseling Graduate Certificate program.
Students enter the profession because they have a deep desire to help individuals recover and sustain the recovery of persons with mental and substance use disorders. Antwan McKenzie-Plez entered the program for that reason. “I am prepared to make a positive impact on lives. Union has given me the best training possible.”
“Our mission is to support every student as a future professional colleague in gaining counseling concepts and skills, but also encourage reflective personal growth,” said Rosalyn Y. Brown Beatty, Ph.D., LPC, NCC, Director, Masters of Arts in Clinical Mental Health Counseling and Alcohol & Drug Abuse Counseling – Graduate Certificate Program.
Antwan agrees. “The self-knowledge I have acquired through my studies at Union allows me to be a better counselor. I just completed my internship and was hired by the company because of my excellent training.”
September is National Recovery Month and offers the opportunity to highlight the important work of the M.A. with a major in Clinical Mental Health Counseling and Alcohol & Drug Abuse Counseling – Graduate Certificate Program.
“The M.A. is accredited by the Council for Accreditation of Counseling and Related Educational Programs (CACREP) and led by scholar practitioners. Our accreditation ensures that students receive a curriculum based on the highest educational standards. CACREP is the accrediting body for master's and doctoral degree programs in counseling and its specialties offered by colleges and universities in the United States and the world,” said Dr. Brown Beatty. “Our counselor educators pride themselves on being able to teach the theories, techniques, and skills required to become a counselor using decades of combined counseling experience to adequately prepare students to become practitioners in the field of counseling and building connection to the broader counseling professional network,” said Dr. Brown Beatty.
The Union certificate in Alcohol and Drug Abuse Counseling is a fully online graduate certificate offered as a stand-alone program or embedded in the M.A. major in Clinical Mental Health Counseling.
“This program trains and prepares professionals for a career in counseling individuals with substances use and abuse problems,” said Dr. Brown Beatty. “The certificate can be completed in just one year. An alcohol and drug abuse counselor specializes in providing counseling and support to individuals and families experiencing problems with substance use or dependence. This may include individual, family or group counseling about the causes and effects of addiction support for families dealing with addiction, and/or referrals to treatment.”
A benefit only available to Union students is the fully online library. Access to the library is a service few universities can match. It provides access to a growing collection of more than 125,000 electronic full-text periodicals via 150+ online licensed research databases, available to students 24/7, 365 days a year.
In addition, career services leads students to employers looking for their skill set through the job alert network. The career counselor also offers resume and interview services to successfully market students to a rewarding career.
The U.S. Bureau of Labor Statistics (BLS) estimates a high growth rate for both occupations with a salary range of $39,000 to $65,680 for the mental health counselor field and a salary range of $39,600 to $73,050 for a drug and alcohol counselor.
“Union is known for transforming lives and communities. The UI&U Master of Arts with a major in Clinical Mental Health Counseling or Alcohol and Drug Abuse Counseling Graduate Certificate program offers the opportunity to enter a rewarding profession that makes measurable improvement in the quality of the lives of clients, families, and society,” said Dr. Brown Beatty.
About Union Institute & University
Union Institute & University is a non-profit, regionally accredited university specializing in providing quality higher education degrees for adults nationwide. Founded in 1964, Union’s academic programs and services are the result of more than five decades of identifying and refining ways to structure and deliver education to meet the needs of adults. Distinguished as the pioneer in adult education, Union perfected the concepts now common in higher education such as the hybrid model, a blend of online and traditional classroom instruction, interdisciplinary studies, and student centered education with socially relevant and applicable learning outcomes in its undergraduate, master’s and doctoral degree programs.
The university is guided by its core mission to educate highly motivated adults who seek academic programs to engage, enlighten, and empower them to pursue professional goals and a lifetime of learning, service, and social responsibility.
Union is a national university with academic centers located in: Ohio, Florida, and California.
Watching an Embryo’s Neural Tube Close
First-in-Class Technology to Deliver Images of Birth Defect as it Happens
HOUSTON, Sept. 4 – In those precious weeks before a woman even realizes she’s pregnant, an embryo will have already developed a neural tube, a hollow structure made of cells which will eventually become the brain and spinal cord. Now, with $3.2 million from the National Institutes of Health, UH professor of biomedical engineering Kirill Larin will tackle the evolutionary anomaly of why the neural tube closes in most embryos but remains open in others, leading to birth defects such as spina bifida and anencephaly.
Neural Tube Defects (NTD) are the second most common structural birth defect in humans, affecting upwards of 500,000 pregnancies worldwide and approximately 2,400 pregnancies each year in the United States.
Together with Baylor College of Medicine professor Richard H. Finnell and Giuliano Scarcelli, assistant professor of bioengineering at University of Maryland, Larin will create new technology combining Brillouin spectroscopy and optical coherence tomography (OCT) to deliver 3D images of the mechanical factors at play when the neural tube closes and – in so many cases - when it does not.
Most commonly used to examine the retina, high-resolution OCT is an imaging technology that uses light waves to take cross-section pictures. Brillouin spectroscopy is a light scattering technology that will sense the stiffness of the tissue, which is critical to its success in closing. During malfunctions there are areas of low stiffness, so it is not folding together properly, Larin said.
“We will create this hybrid microscope putting these two powerful technologies together. OCT will image the development of the neural tube while at the same time, Brillouin spectroscopy will probe its mechanical properties. We will be imaging and sensing at the same time,” said Larin.
Finding out how mechanical properties controlling neural tube closure in developing embryos can be manipulated to ensure proper neural development is the first step to exploring treatment for the defect.
“If we find out what causes the tube to close, what is exactly happening, we can develop new drug treatments for at-risk embryos,” said Larin.
The work fills a significant data gap in understanding neural tube closure biomechanics.
“It’s still one of the great mysteries of life, no one on earth knows how this happens and that is really exciting to us,” said Larin, “because we will be the ones to find out.”
About the University of Houston
The University of Houston is a Carnegie-designated Tier One public research university recognized with a Phi Beta Kappa chapter for excellence in undergraduate education. UH serves the globally competitive Houston and Gulf Coast Region by providing world-class faculty, experiential learning and strategic industry partnerships. Located in the nation's fourth-largest city and one of the most ethnically and culturally diverse regions in the country, UH is a federally designated Hispanic- and Asian-American-Serving institution with enrollment of more than 45,000 students.
How Seniors Can Truly Benefit from Low-Impact Workouts
Activity is vital at any life stage. It helps children develop correctly, keeps adults healthy and reduces the impact of old age in seniors. Elders that stay active can enjoy various benefits to their well-being, even from low-impact workouts.
Still, it isn’t always easy to keep motivated to work out, especially during these hot summer days. To avoid loss of motivation, seniors should always keep in mind how beneficial exercise can be for them. Let’s have a look at how seniors can genuinely benefit from low-impact workouts, as well as what the best low-impact workouts are.
Better Mental Health
Whichever form of exercise you choose, it’s sure to produce endorphins. Activities in nature will further increase the impact of the “feel good” hormone, ensuring you’ll feel satisfied and happy afterward. Nature walks or hikes, cycling, and yoga can serve you well in reducing bad moods and improve your overall mental health. Exercise has an exceptionally positive impact on insomnia and other sleeping problems, which are common in seniors.
Better Physical Health
Regular activity prevents or lowers the risk of many illnesses, and keeps your body strong and healthy. Working out improves our immune system, which is especially crucial for elders since they are more vulnerable to diseases. But low-impact workouts don’t only keep diseases at bay. They also reduce the risk of falling by improving strength, flexibility, balance, and coordination. Even the most basic low-impact exercise like walking can help, as long as it’s done regularly.
More Social Engagement
One of the best things about exercise is that it doesn’t have to be a solitary activity. Like-minded seniors can get together for walks or hiking. Having company usually improves accountability as well, so you’ll be more motivated to keep up with your workout habits. Another right way to stay active while enjoying company, is signing up for dancing or a fitness class. By maintaining social ties, you’ll keep loneliness at bay as well.
Improved Brain Function
According to multiple studies, physical activity also has a positive influence on our cognitive function. Exercise improves and fine-tunes our motor skills, which in turn keeps our mind sharp. Active seniors are in less of a risk from dementia, regardless of whether they’ve always been active or not. What matters is that you stay physically active.
Best Low-Impact Exercises
Sometimes seniors can find the idea of exercise intimidating due to fear of falling or injury. It is precisely why low-impact workouts are recommended as they are relatively easy compared to full-blown workout routines. Walking is the easiest one to get into but provides a full-body workout. The same goes for swimming, which is considered to be one of the safest solutions for exercising when joint health is in question. Stretching and yoga are great for building flexibility and balance or maintaining them in old age. Alternatively, you might want to take up cycling, dancing or tai chi.
Ultimately, staying active is one of the best ways to ensure a good quality of life even if you’re well into your senior years. And if you’re experiencing any orthopaedic problems, professionals at Florida Orthopaedic Institute are here to help. Schedule an appointment today to start feeling better tomorrow.
Elizabeth Domenech, national strategies pr
Office: (813) 865-3093 I Mobile: (787) 587-3213
3030 North Rocky Point Drive West, Suite 150, Tampa, FL 33607
Confidential: This electronic message and all contents contain information from National Strategies Public Relations which may be privileged, confidential or otherwise protected from disclosure. The information is intended to be for the addressee only. If you are not the addressee, any disclosure, copy, distribution or use of the contents of this message is prohibited. If you have received this electronic message in error, please notify the sender and destroy the original message and all copies.
If you would rather not receive future communications from Florida Orthopaedic Institute, let us know by clicking here.
Florida Orthopaedic Institute, 909 N. Dale Mabry Hwy, Suite 201 Suite 201, Tampa, Florida 33609 United States
" src="blob:http://www.trainitright.com/2c02cb70-4310-4679-84c7-859ba61510e8" alt="Christopher Grayson M.D..jpg" type="application/x-apple-msg-attachment" class="Apple-web-attachment Singleton" style="caret-color: rgb(0, 0, 0); color: rgb(0, 0, 0); font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; text-decoration: none; font-family: Helvetica; font-size: 12px;">
Ampersand Invests in Management Buyout of Clinical Immunology Provider NEOMED-LABS from the NEOMED Institute
LAVAL, QC and WELLESLEY, MA, Sept. 4, 2018 /CNW Telbec/ - Ampersand Capital Partners, together with the management team of NEOMED-LABS and the NEOMED Institute, announced today that Ampersand has partnered with management in the acquisition of NEOMED-LABS from its not-for-profit founder and parent, the NEOMED Institute.
NEOMED-LABS is a leading provider of clinical immunology laboratory services for biologics drug development, with extensive experience supporting the development of novel vaccines. Formed in April 2015 as a spin-out from GSK's Clinical Laboratory Services unit, NEOMED-LABS has built on its world-renowned expertise in clinical immunology to form partnerships with many of the top 10 global vaccine developers, innovative biotechnology companies, and prestigious governmental and non-governmental organizations. Ampersand's investment positions NEOMED-LABS to pursue both organic and acquisition-related growth initiatives, including expansion into adjacent markets and geographies as well as to continue to expand its presence in Quebec.
"After a successful spin-out from GSK and strong business performance during its first three years of operation, this investment from Ampersand will help NEOMED-LABS achieve the next level in its evolution and support the growing needs of our customers," said Benoit Bouche, President and Chief Executive Officer of NEOMED-LABS. "We are extremely pleased to enter into this new partnership with Ampersand, given their unique experience in helping laboratory-based pharmaceutical services companies like NEOMED-LABS grow. Their strategic insights will undoubtfully help us continue fueling our rapid growth trajectory, broaden our customer base and pursue our international expansion."
"We are excited to partner with Benoit Bouche and his team at NEOMED-LABS" stated Eric Lev, Partner at Ampersand. "We believe NEOMED-LABS has tremendous potential in the clinical immunology field. Our goal is to actively support management to build the company into the world class leader of immunology-related assay development and clinical trial laboratory services."
Donald Olds, President and CEO of the NEOMED Institute added: "I am very pleased with the closing of this strategic transaction. The NEOMED Institute formed NEOMED-LABS in 2015 to preserve over 50 high paying R&D positions in Quebec and we have accomplished our mission. This transaction positions NEOMED-LABS for future success through access to new capital and the international network and expertise of Ampersand. I am highly confident that this new partnership will lead to significant future business and employment growth for the benefit of the Quebec and Canadian life sciences industry, which is a core objective of the NEOMED Institute."
ABOUT NEOMED-LABS
NEOMED-LABS is a leading, independent, pure player in the immunology field whose team of experts and state of the art BSL2 labs were instrumental in the development, qualification, and validation of more than 30 assays supporting the FDA filing of 10 marketed vaccines whose cumulative sales is around $3bn. Our unrivaled expertise in immunotools engineering and stability testing, as well as our capacity of 200k results per year on our immunochemistry, virology, and bacteriology automated platforms are devoted to personalized services and fast track method validation.
For more information, please visit: www.neomedlabs.com
ABOUT AMPERSAND CAPITAL PARTNERS
Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories.
For more information, please visit: www.ampersandcapital.com
ABOUT THE NEOMED INSTITUTE
The NEOMED Institute is a successful and innovative Canadian not-for-profit R&D organization whose mission is to enable and accelerate the commercialization of life science discoveries. NEOMED Institute operates two complementary and integrated divisions: NEOMED Therapeutics in-licenses promising scientific discoveries from Canadian university centres and research institutes and then funds and develops these programs to stages that are attractive for partnering or stand-alone financing; and NEOMED Innovation Centre operates a world-class life sciences ecosystem in Montreal, Quebec hosting 30 life sciences companies employing over 350 people who operate in our two state-of-the-art R&D centres. The NEOMED Institute is funded by pharmaceutical partners, Quebec's Ministry of the Economy of Science and Innovation, and the Networks of Centres of Excellence of Canada.
For more information, please visit: www.neomed.ca
SOURCE NEOMED-LABS Inc.
Baxter announces Health Canada approval of OLIMEL 7.6% high protein Parenteral Nutrition formulations
- Highest protein and lowest glucose formulation among Parenteral Nutrition (PN) products (with or without electrolytes) available in a standardized, triple-chamber bag1,2,3,4
- New PN formulation will help meet needs of high stress patients who require more protein and are often impacted by hyperglycemia
- OLIMEL 7.6% and 7.6% E are the latest additions to Baxter's olive oil-based parenteral nutrition portfolio
MISSISSAUGA, ON, Sept. 4, 2018 /CNW/ - Baxter Canada, a leader in nutrition therapy, today announced Health Canada approval of OLIMEL 7.6% and OLIMEL 7.6% E (amino acids, dextrose, lipids with/without electrolytes, injectable emulsion) for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated. These OLIMEL 7.6% nutrition solutions are the latest additions to the company's olive oil-based parenteral nutrition portfolio. As a ready-to-use solution, OLIMEL 7.6% (with or without electrolytes) is designed to meet the needs of high-risk patients by combining the highest protein with the lowest glucose formulation available in a standardized, triple-chamber bag.
Critically-ill patients and those who have major surgery may require parenteral nutrition, which may be necessary when a patient cannot get adequate nutrients orally or through tube feeding. Most of these patients receive less than half of the protein that is recommended for more than 10 days in the ICU5. While recent studies show that higher protein treatments were associated with lower mortality rates in the ICU6,7 giving patients more protein with ready-to-use products can have the unintended consequence of increasing their intake of glucose and potentially lead to overfeeding.
"Through our focus on innovation, Baxter is able to bring OLIMEL 7.6% and OLIMEL 7.6% E, our latest parenteral nutrition products, to Canadian hospitals," said James Teaff, Business Unit Head, Hospital Products. "Clinicians now have two new nutritional solutions to help their adult patients reach their protein targets, regain their health sooner and minimize hospital stays."
Baxter's latest OLIMEL 7.6% formulations provide clinicians new options for treating critically-ill patients, as they include:
- 76g of protein (amino acid) per liter, designed to deliver protein targets in lower fluid volumes.
- Only 73g of glucose per liter which helps reduce the risk of hyperglycemia.
- Olive oil-based lipid emulsions that may preserve immune function 8,9,10,11,12.
The use of high protein regimens and olive oil-based lipid emulsions are supported by ASPEN guidelines.
Consult the OLIMEL product monograph at: http://www.baxter.ca/en_CA/assets/downloads/monographs/OLIMEL_EN.pdf
for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available through the Baxter medical department.
About Baxter Canada
Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For over 80 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. Baxter Canada and its nearly 1,000 employees are located primarily in Ontario at the Head Office, CIVA Admixing and Technical Services Centres in Mississauga, and in Alliston – where Baxter operates Canada's only large scale manufacturing plant producing life-sustaining intravenous and dialysis solutions. To learn more, visit www.baxter.ca and follow us on Twitter, LinkedIn and Facebook.
Baxter and OLIMEL are registered trademarks of Baxter International Inc.
| __________________________ |
| 1 |
OLIMEL N12 SmPC, 2017. |
| 2 |
SmofKabiven SmPC, 2017. |
| 3 |
NutriFlex SmPC, 2015. |
| 4 |
Trimix HP SmPC, 2017. |
| 5 |
Hoffer and Bistrian. Am J Clin Nutr 2012;96:591–600. |
| 6 |
Elke G et al. Critical Care 2014;18:R29. |
| 7 |
Allingstrup Clinical Nutrition 2012;32: 460=18. |
| 8 |
Jia Nutrition Journal 2015;14-119. |
| 9 |
Calder PC, et al. Intensive Care Med 2010;36:735-49. |
| 10 |
Granato D, et al. JPEN J Parenter Enteral Nutr 2000;24:113-8. |
| 11 |
Olthof E, et al. Clin Nutr 2013;32:643-649. 4. Pontes-Arruda A, Clin Nutr Suppl 2009;4:19-23. 5. |
| 12 |
Waitzberg DL, et al. JPEN J Parenter Enteral Nutr 2006;30:351-67. |
SOURCE Baxter Corporation
Sunstar Supports Release of Chairside Guide on Prevention and Treatment of Oral Cancer
BUENOS AIRES, Sept. 3, 2018 /CNW/ - Sunstar is proud to announce the launch of Oral Cancer: Prevention and patient management, an FDI World Dental Federation chairside guide for oral health professionals. The guide is supported by Sunstar and aims to mitigate the effects of oral cancer by promoting comprehensive oral cancer screenings as an integral part of routine dental check-ups. It highlights the most common risk factors for oral cancer and underlines the importance of early diagnosis and treatment by providing practical solutions for the care pathway.
The guide was released today at the FDI World Dental Congress in Buenos Aires, Argentina. "FDI recognizes that oral health professionals play an essential role in combatting oral cancer," said Dr Kathryn Kell, FDI President. "Oral cancer is among the 10 most common cancers worldwide, but oral health professionals can help diminish its effects through early detection and swift treatment action."
The chairside guide provides oral health professionals with concise, yet comprehensive, information about oral cancer prevention, risk factors and management, and also helps them navigate the clinical examination and diagnosis through a decision tree. It focuses on the most common sites of oral cancer: the tongue, the insides of the cheeks, and the floor of the mouth.
"At Sunstar, we constantly investigate the power of a holistic approach to health to prevent and treat life-threatening conditions as early as possible. This chairside guide is a great example of a tool that supports health professionals in their daily patient screenings. Dental check-ups can be the perfect setting for early detection of several diseases, providing a central prevention role to dental professionals," said Dr Marzia Massignani, Sr Manager of Scientific Affairs at Sunstar.
Survival rates for oral cancer can be improved through early detection. Therefore, it is essential that oral health professionals such as dentists, dental hygienists, dental therapists and oral health therapists understand the importance of conducting a thorough oral screening examination for malignant and potentially malignant lesions as part of their routine clinical assessments, even in younger populations considered at lower risk for oral cancer. The chairside guide encourages and facilitates the integration of this examination into routine dental check-ups.
"About 500,000 new cases of oral and oropharyngeal cancers are diagnosed annually, three-quarters of which occur in the developing world," said Dr Ihsane Ben Yahya, FDI Council member and oral cancer expert. "FDI is committed to reducing the oral disease burden and improving oral health outcomes worldwide. By designing an informative tool to prevent,promptly detect and treat oral cancer, we act in line with our mission to lead the world to optimal oral health."
Oral Cancer: Prevention and patient management is available to consult and download on the Sunstar GUM website, and print copies in English and Spanish will be distributed at the FDI World Dental Congress at the Sunstar booth in Buenos Aires, Argentina.
About Sunstar
With an eye to the future, Sunstar's vision is to pioneer a new era of innovation, champion new invigorating partnerships, and speak to the heart of a new generation of global consumers. We strive to help people everywhere achieve better health and enhance their quality-of-life through our products and services. Based on our corporate motto "Always strive to help people everywhere achieve better health and enhance their quality-of-life", the Sunstar Group will continue to be attentive and responsive to the varied needs and expectations of our global consumers. http://www.sunstar.com/company/philosophy
About FDI World Dental Federation
FDI World Dental Federation is an international, membership-based organization that serves as the main representative body for more than 1 million dentists worldwide, active in some 200 National Dental Associations (NDAs) and specialist groups in close to 130 countries. FDI has a bold vision: to lead the world to optimal oral health. Speaking as the unified voice of dentistry, we collaborate closely with our members, oral health experts, allied health professionals, and industry partners alike to achieve this vision together. http://www.fdiworlddental.org; http://www.facebook.com/FDIWorldDentalFederation; http://www.twitter.com/fdiworlddental
SOURCE Sunstar
